Targeting inflammation to reduce ASCVD in type 2 diabetes

Journal of Diabetes and its Complications

Volumn 33, Issue 1, 2019, Pages 1-3

  Jialal, Ishwarlal ^a,b   Chaudhuri, Ajay ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b California Northstate University   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Atherosclerosis; Diabetes; GLP 1 receptor agonist; Inflammation; Interleukin 1; Statin

Indexed keywords

CANAKINUMAB; COLCHICINE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; LIRAGLUTIDE; LIXISENATIDE; METHOTREXATE; SALSALATE; SEMAGLUTIDE; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN; INFLAMMATION; INSULIN TREATMENT; MEDITERRANEAN DIET; MEDLINE; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; ATHEROSCLEROSIS; COMPLICATION; IMMUNOLOGY;

ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; DIET, MEDITERRANEAN; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION;

EID: 85057496480     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2018.11.001     Document Type: Note

References (31)

1. Jialal, I., Devaraj, S., Anti-inflammatory strategies to prevent diabetic cardiovascular disease. Clin Pharmacol Ther 98 (2015), 121–123.
2. Low Wang, C.C., Hess, C.N., Hiatt, W.R., Goldfine, A.B., Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations. Circulation 133 (2016), 2459–2502.
3. Devaraj, S., Dasu, M.R., Jialal, I., Diabetes is a proinflammatory state: a translational perspective. Expert Rev Endocrinol Metab 5 (2010), 19–28.
4. Soinio, M., Marniemi, J., Laakso, M., Lehto, S., Ronnemaa, T., High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study. Diabetes Care 29 (2006), 329–333.
5. Estruch, R., Ros, E., Salas-Salvado, J., et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med, 378, 2018, e34.
6. Ridker, P.M., From C-reactive protein to Interleukin-6 to Interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res 118 (2016), 145–156.
7. Dandona, P., Ghanim, H., Chaudhuri, A., Incretins: beyond type 2 diabetes. Diabetes Obes Metab 20 (2018), 59–67.
8. Shiraki, A., Oyama, J., Komoda, H., et al. The glucagon-like peptide 1 analog liraglutide reduces TNF-alpha-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis 221 (2012), 375–382.
9. Hogan, A.E., Gaoatswe, G., Lynch, L., et al. Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia 57 (2014), 781–784.
10. Nauck, M.A., Meier, J.J., Cavender, M.A., Abd El Aziz, M., Drucker, D.J., Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation 136 (2017), 849–870.
11. Dai, Y., Mehta, J.L., Chen, M., Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation. Cardiovasc Drugs Ther 27 (2013), 371–380.
12. Mazidi, M., Karimi, E., Rezaie, P., Ferns, G.A., Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Diabetes Complications 31 (2017), 1237–1242.
13. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
14. Marso, S.P., Bain, S.C., Consoli, A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
15. Chen, W.R., Hu, S.Y., Chen, Y.D., et al. Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J 170 (2015), 845–854.
16. Mann, J.F.E., Orsted, D.D., Brown-Frandsen, K., et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377 (2017), 839–848.
17. Dandona, P., Aljada, A., Mohanty, P., et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect?. J Clin Endocrinol Metab 86 (2001), 3257–3265.
18. Chaudhuri, A., Janicke, D., Wilson, M.F., et al. Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation 109 (2004), 849–854.
19. Selker, H.P., Beshansky, J.R., Sheehan, P.R., et al. Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. JAMA 307 (2012), 1925–1933.
20. Investigators OT, Gerstein, H.C., Bosch, J., et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367 (2012), 319–328.
21. Ridker, P.M., Everett, B.M., Thuren, T., et al. Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med 377 (2017), 1119–1131.
22. Everett, B.M., Donath, M.Y., Pradhan, A.D., et al. Anti-inflammatory therapy with Canakinumab for the prevention and management of diabetes. J Am Coll Cardiol 71 (2018), 2392–2401.
23. Libby, P., Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond. J Am Coll Cardiol 70 (2017), 2278–2289.
24. Goldfine, A.B., Fonseca, V., Jablonski, K.A., et al. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med, 159, 2013, 12.
25. Hauser, T.H., Salastekar, N., Schaefer, E.J., et al. Effect of targeting inflammation with Salsalate: the TINSAL-CVD randomized clinical trial on progression of coronary plaque in overweight and obese patients using statins. JAMA Cardiol 1 (2016), 413–423.
26. Ridker, P.M., Luscher, T.F., Anti-inflammatory therapies for cardiovascular disease. Eur Heart J 35 (2014), 1782–1791.
27. McInnes, I.B., Thompson, L., Giles, J.T., et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis 74 (2015), 694–702.
28. Stanley, T.L., Zanni, M.V., Johnsen, S., et al. TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab 96 (2011), E146–E150.
29. Nidorf, S.M., Eikelboom, J.W., Budgeon, C.A., Thompson, P.L., Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 61 (2013), 404–410.
30. Jialal, I., Vikram, N.K., Inflammation and atherosclerosis: fulfilling Koch's postulates. Ther Adv Cardiovasc Dis 12 (2018), 5–6.
31. Ridker, P., et al. Low dose methotrexate the prevention of atherosclerotic events. N Engl JMed, 2018 PMID 30415610.